Cargando…

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer

The use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors represents a potent strategy for cancer therapy. Due to the complex molecular network that regulates cell cycle progression, cancer cells often acquire resistance mechanisms against these inhibitors. Previously, our group identified molecula...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Florian G., Granier, Charlène, Zhao, Yuling, Pan, Qi, Tong, Zhichao, Gschwend, Jürgen E., Holm, Per Sonne, Nawroth, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145096/
https://www.ncbi.nlm.nih.gov/pubmed/33923231
http://dx.doi.org/10.3390/jpm11050340
_version_ 1783697100536545280
author Klein, Florian G.
Granier, Charlène
Zhao, Yuling
Pan, Qi
Tong, Zhichao
Gschwend, Jürgen E.
Holm, Per Sonne
Nawroth, Roman
author_facet Klein, Florian G.
Granier, Charlène
Zhao, Yuling
Pan, Qi
Tong, Zhichao
Gschwend, Jürgen E.
Holm, Per Sonne
Nawroth, Roman
author_sort Klein, Florian G.
collection PubMed
description The use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors represents a potent strategy for cancer therapy. Due to the complex molecular network that regulates cell cycle progression, cancer cells often acquire resistance mechanisms against these inhibitors. Previously, our group identified molecular factors conferring resistance to CDK4/6 inhibition in bladder cancer (BLCA) that also included components within the DNA repair pathway. In this study, we validated whether a combinatory treatment approach of the CDK4/6 inhibitor Palbociclib with Poly-(ADP-Ribose) Polymerase (PARP) inhibitors improves therapy response in BLCA. First, a comparison of PARP inhibitors Talazoparib and Olaparib showed superior efficacy of Talazoparib in vitro and displayed high antitumor activity in xenografts in the chicken chorioallantoic membrane (CAM) model. Moreover, the combination of Talazoparib and the CDK4/6 inhibitor Palbociclib synergistically reduced tumor growth in Retinoblastoma protein (RB)-positive BLCA in vitro and in a CAM model, an effect that relies on Palbociclib-induced cell cycle arrest in G0/G1-phase complemented by a G2 arrest induced by Talazoparib. Interestingly, Talazoparib-induced apoptosis was reduced by Palbociclib. The combination of Palbociclib and Talazoparib effectively enhances BLCA therapy, and RB is a molecular biomarker of response to this treatment regimen.
format Online
Article
Text
id pubmed-8145096
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81450962021-05-26 Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer Klein, Florian G. Granier, Charlène Zhao, Yuling Pan, Qi Tong, Zhichao Gschwend, Jürgen E. Holm, Per Sonne Nawroth, Roman J Pers Med Article The use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors represents a potent strategy for cancer therapy. Due to the complex molecular network that regulates cell cycle progression, cancer cells often acquire resistance mechanisms against these inhibitors. Previously, our group identified molecular factors conferring resistance to CDK4/6 inhibition in bladder cancer (BLCA) that also included components within the DNA repair pathway. In this study, we validated whether a combinatory treatment approach of the CDK4/6 inhibitor Palbociclib with Poly-(ADP-Ribose) Polymerase (PARP) inhibitors improves therapy response in BLCA. First, a comparison of PARP inhibitors Talazoparib and Olaparib showed superior efficacy of Talazoparib in vitro and displayed high antitumor activity in xenografts in the chicken chorioallantoic membrane (CAM) model. Moreover, the combination of Talazoparib and the CDK4/6 inhibitor Palbociclib synergistically reduced tumor growth in Retinoblastoma protein (RB)-positive BLCA in vitro and in a CAM model, an effect that relies on Palbociclib-induced cell cycle arrest in G0/G1-phase complemented by a G2 arrest induced by Talazoparib. Interestingly, Talazoparib-induced apoptosis was reduced by Palbociclib. The combination of Palbociclib and Talazoparib effectively enhances BLCA therapy, and RB is a molecular biomarker of response to this treatment regimen. MDPI 2021-04-24 /pmc/articles/PMC8145096/ /pubmed/33923231 http://dx.doi.org/10.3390/jpm11050340 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Klein, Florian G.
Granier, Charlène
Zhao, Yuling
Pan, Qi
Tong, Zhichao
Gschwend, Jürgen E.
Holm, Per Sonne
Nawroth, Roman
Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
title Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
title_full Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
title_fullStr Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
title_full_unstemmed Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
title_short Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
title_sort combination of talazoparib and palbociclib as a potent treatment strategy in bladder cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145096/
https://www.ncbi.nlm.nih.gov/pubmed/33923231
http://dx.doi.org/10.3390/jpm11050340
work_keys_str_mv AT kleinfloriang combinationoftalazoparibandpalbociclibasapotenttreatmentstrategyinbladdercancer
AT graniercharlene combinationoftalazoparibandpalbociclibasapotenttreatmentstrategyinbladdercancer
AT zhaoyuling combinationoftalazoparibandpalbociclibasapotenttreatmentstrategyinbladdercancer
AT panqi combinationoftalazoparibandpalbociclibasapotenttreatmentstrategyinbladdercancer
AT tongzhichao combinationoftalazoparibandpalbociclibasapotenttreatmentstrategyinbladdercancer
AT gschwendjurgene combinationoftalazoparibandpalbociclibasapotenttreatmentstrategyinbladdercancer
AT holmpersonne combinationoftalazoparibandpalbociclibasapotenttreatmentstrategyinbladdercancer
AT nawrothroman combinationoftalazoparibandpalbociclibasapotenttreatmentstrategyinbladdercancer